



(51) International Patent Classification:

A61K 31/137 (2006.01) A61P 11/02 (2006.01)
A61K 31/135 (2006.01) A61P 11/12 (2006.01)
A61K 31/167 (2006.01)

(21) International Application Number:

PCT/NZ2014/000001

(22) International Filing Date:

7 January 2014 (07.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

606659	4 February 2013 (04.02.2013)	NZ
610132	2 May 2013 (02.05.2013)	NZ
613918	2 August 2013 (02.08.2013)	NZ
618027	20 November 2013 (20.11.2013)	NZ

(71) Applicant: **AFT PHARMACEUTICALS LIMITED**
[NZ/NZ]; Level 1, Neilsen Building, 129 Hurstmere Road,
Takapuna, Auckland, 0740 (NZ).

(72) Inventor: **ATKINSON, Hartley Campbell**; 16 Brett Avenue,
Takapuna, Auckland, 0622 (NZ).

(74) Agent: **PIETRAS, Anthony Josef**; AJ Pietras & Co, Level
2, 1 Margaret Street, (PO Box 30173), Lower Hutt, Wellington,
5010 (NZ).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: A COMBINATION MEDICAMENT COMPRISING PHENYLEPHRINE AND PARACETAMOL

Figure 1

Mean Plasma Phenylephrine Hydrochloride Concentration (Linear)



(57) Abstract: Use of phenylephrine hydrochloride (or a pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in the production of a combination medicament for treating upper respiratory mucosal congestion, comprising combining such substances with excipients, characterised in that the medicament has the phenylephrine hydrochloride (or the pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in proportions suitable for, and the medicament is for, providing an adult with: a) 4 mg - 7.5 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 950 mg - 1,000 mg paracetamol; or b) 5 mg - 7.5 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 600 mg - 700 mg paracetamol; or c) 6 mg - 8 mg phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine), in combination with 500 mg - 550 mg paracetamol.